About ▼ Careers Internship MedBlog Contact us

LOGIN REGISTER

Medindia » News » Drug News » ISP Drug may Lead to Spinal Cord Injury Treatments

ISP Drug may Lead to Spinal Cord Injury Treatments

by Bidita Debnath on Dec 4 2014 10:41 PM

ISP Drug may Lead to Spinal Cord Injury Treatments

The barrier-breaking ISP drug did not cause spinal cord axons known to control movements to cross the scar and reconnect with brain neurons above the injury site.

Dr. Silver and his colleagues think this means the ISP-induced sprouting helped the rats recover by increasing the signal sent by the few remaining intact axons.

Green Tea Protects the Brain During Spinal Cord Injury

Green Tea Protects the Brain During Spinal Cord Injury
In case of a spinal cord injury, the polyphenols in green tea can protect people's brain, reveals new research.

"This is very promising. We now have an agent that may work alone or in combination with other treatments to improve the lives of many," said Dr. Silver. He and his colleagues are seeking to test the ISP drug in preclinical trials.

Source-Eurekalert

Peptide Shows Extraordinary Promise for Treating Spinal Cord Injury

Peptide Shows Extraordinary Promise for Treating Spinal Cord Injury
Scientists at Case Western Reserve University School of Medicine have developed a new chemical compound that shows extraordinary promise in restoring function lost to spinal cord injury.

Spinal Cord Injury Victims may Benefit from Stem Cell Transplantation Studies: Study

Spinal Cord Injury Victims may Benefit from Stem Cell Transplantation Studies: Study
Stem cell transplantation may be an effective treatment option for spinal cord injury (SCI), say researchers.

Presence of Enzyme may Worsen Effects of Spinal Cord Injury, Suggests Research

Presence of Enzyme may Worsen Effects of Spinal Cord Injury, Suggests Research
Previous research has shown that traumatic spinal cord injury (SCI) is a devastating condition with few treatment options.

Recommended Readings

Hemiplegia

Hemiplegia is a condition that is characterized by paralysis of one half of the body, usually due to a brain lesion on the opposite side. It may be congenital (cerebral palsy) or acquired later in life due to illness.

Spinal Injury - Symptom Evaluation

Spinal Injury - Symptom Evaluation

Spinal Injury refers to damage to spinal cord that runs below the brain through the back. Injury to spinal cord is a severe injury as the damage is irreversible and it can be life-threatening.

Spinal Cord Injury

Spinal Cord Injury

Spinal cord injury is an injury to the spinal cord that results in temporary or permanent changes in its function.

Autonomic Dysreflexia

Autonomic Dysreflexia

Autonomic dysreflexia is a condition that occurs in patients with spinal cord injuries especially in the T5 and T6 levels. This condition is characterized by hyper activity of the autonomic nervous system.

Athletes Foot

Athlete’s foot (tinea pedis/ringworm of the foot) is a fungal infection of the feet.

Spondylolisthesis

Spondylolisthesis

Spondylolisthesis is a condition of the lower spine in which one of the bones of the vertebral column slips out of its proper place and slides over to the vertebra below it.

Latest Drug News

Alectinib: Adjuvant Treatment for Lung Cancer Approved by US FDA

Alectinib: Adjuvant Treatment for Lung Cancer Approved by US FDA

Alectinib approved by US FDA for auxiliary treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who underwent tumor resection.

US FDA Approval of N-803: Ray of Hope For Bladder Cancer Patients

US FDA Approval of N-803: Ray of Hope For Bladder Cancer Patients

The US FDA approves a immunotherapy drug, N-803, for BCG-unresponsive non-muscle invasive bladder cancer, suggested to be used in conjunction with BCG.

Resmetirom For MASH: Approved by US FDA, Increase in Partnerships

Resmetirom For MASH: Approved by US FDA, Increase in Partnerships

The increasing trend in strategic partnerships between innovator companies, and the US FDA approval for Rezdiffra has led to a boost in the development of medications for MASH.

Semaglutide: A Dominant Player for Patients With Heart Failure

Semaglutide: A Dominant Player for Patients With Heart Failure

Data provesSemaglutideefficacy in treatment of Type 2 diabetes, obesity, heart failure, and chronic kidney failure, it emerges as important therapy in metabolic syndrome.

Physician's Lack Agreement – Patients Prefer Branded or Generic Drugs?

Physician's Lack Agreement – Patients Prefer Branded or Generic Drugs?

Generics are not widely used, despite cost advantage, due to a lack of information to patients and reluctance from physicians to prescribe generics - A Need to educate masses

Advertisement